Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 726 participants.
Also called NCT07734792
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 726 participants
- Sponsor
- yifang zhu
- Registry
-
NCT07734792
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07734792. Randomized; single masking; primary purpose treatment. Start 2026-09-26 (actual); primary completion 2028-05-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
- Acronym
- TOPAZ
- Condition
- Acute Ischemic Stroke (AIS)
- Intervention (Drug)
- Tirzepatide
- Intervention (Other)
- Standard Medical Care (SMC)
- Lead sponsor
- yifang zhu
Record details
- Record id
cardio:ct-nct07734792- Content hash
4e1f844ad57f8860dae870b1f64c71ed45d1c68fcc4061fa550f9d5c995e028a